Full year 2025 financial guidance excludes any potential share repurchase or additional M&A activity. CEO Dr. Steve Cutler commented, "ICON continues to navigate dynamic clinical development ...
Truist Financial analyst Jailendra Singh assigned a Buy rating to Icon (ICLR – Research Report) today and set a price target of $284.00. The company’s shares closed yesterday at $203.26.
ICON plc, (NASDAQ: ICLR), a world-leading clinical research organization powered by healthcare intelligence, today announced its financial guidance for the year ending December 31, 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback